Short-Term Safety and Efficacy of Low-Dose Simvastatin in Elderly Patients with Hypertensive Hypercholesterolemia and Fasting Hyperinsulinemia
Corresponding Author
Dr. Paul Chan MD, PhD
Division of Cardiology and Clinical Pharmacology, Taipei Medical College, Taipei Municipal Wan-Fang Hospital, Taipei, Taiwan
No. 87, Hsin Lung Road, Section 3, Wen Shan, Taipei, Taiwan 117.Search for more papers by this authorDr. Tsuei-Yuen Huang MD
Department of Medicine, Chi-Mei Foundation Hospital, The Chinese University of Hong Kong, Hong Kong
Search for more papers by this authorDr. Brian Tomlinson MD
Department of Clinical Pharmacology, The Chinese University of Hong Kong, Hong Kong.
Search for more papers by this authorMs. Clarita Lee BSc
Division of Cardiology and Clinical Pharmacology, Taipei Medical College, Taipei Municipal Wan-Fang Hospital, Taipei, Taiwan
Search for more papers by this authorDr. Ying-Shiung Lee MD
Department of Medicine, Chang-Gung Memorial Hospital, The Chinese University of Hong Kong, Hong Kong
Search for more papers by this authorCorresponding Author
Dr. Paul Chan MD, PhD
Division of Cardiology and Clinical Pharmacology, Taipei Medical College, Taipei Municipal Wan-Fang Hospital, Taipei, Taiwan
No. 87, Hsin Lung Road, Section 3, Wen Shan, Taipei, Taiwan 117.Search for more papers by this authorDr. Tsuei-Yuen Huang MD
Department of Medicine, Chi-Mei Foundation Hospital, The Chinese University of Hong Kong, Hong Kong
Search for more papers by this authorDr. Brian Tomlinson MD
Department of Clinical Pharmacology, The Chinese University of Hong Kong, Hong Kong.
Search for more papers by this authorMs. Clarita Lee BSc
Division of Cardiology and Clinical Pharmacology, Taipei Medical College, Taipei Municipal Wan-Fang Hospital, Taipei, Taiwan
Search for more papers by this authorDr. Ying-Shiung Lee MD
Department of Medicine, Chang-Gung Memorial Hospital, The Chinese University of Hong Kong, Hong Kong
Search for more papers by this authorAbstract
To evaluate the short-term safety and efficacy of low-dose (10 mg) simvastatin in hypercholesterolemic, hypertensive elderly Chinese patients receiving antihypertensive treatment, a randomized, double-blind, placebo-controlled, 3-month trial was conducted. The patients had a total plasma cholesterol level of at least 250 mg/dL and had been, for at least 3 months, consuming a standard lipid-lowering diet (American Heart Association Step 1 Diet). Elderly hypertensive patients (n = 76) were randomized to receive treatment with either placebo (n = 38) or simvastatin (n = 38). The dosage consisted of 10 mg simvastatin daily during the 3-month trial. During that period, in the simvastatin group, plasma levels of total cholesterol and low-density lipoprotein cholesterol decreased significantly (27% and 33%, respectively) compared with those levels in plasma in the placebo group. The plasma levels of high-density lipoprotein cholesterol increased (7%), whereas triglyceride levels slightly decreased (8%). There were no serious side effects, and simvastatin was generally well tolerated. Fasting hyperinsulinemia also improved (–21%) after 3 months of simvastatin therapy. Results of this study confirmed that a low dose (10 mg) of simvastatin daily is a safe and effective method of reducing plasma levels of total and low-density lipoprotein cholesterol in hypercholesterolemic, hypertensive elderly patients receiving concurrent antihypertensive drug therapy, and that it has the additional potential benefit of reducing plasma levels of insulin.
REFERENCES
- 1 MacMahon SW, Cutler JA, Furberg CD, Payne GH: The effects of drug treatment for hypertension on morbidity and mortality from cardiodisease: a review of randomised controlled trials. Prog Cardiovasc Dis 1986; 29(suppl 1): 99–118.
- 2 Hypertension Detection and Follow-up, Cooperative Group: Five-year findings of the Hypertension Detection and Follow-up Program, I reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 1979; 242: 2562–2571.
- 3 Medical Research Council Working Party: MRC trial for treatment of mild hypertension: Principal results. BMJ 1985; 291: 97–102.
- 4 The Australian Therapeutic Trial in Mild Hypertension: Report by the management committee. Lancet 1980; 1: 1261–1267.
- 5 Hypertension Detection and Follow-up Program, Cooperative Group: Five-year findings of the Hypertension Detection and Follow-up Program, III: Reduction in stroke incidence among persons with high blood pressure. JAMA 1982; 247: 633–638.
- 6 Freis ED: The Veterans Administration Cooperative Study on Antihypertensive Agents: Implications for stroke prevention. Stroke 1974; 5: 76–77.
- 7 Multiple Risk Factor Intervention Trial Research Group: Multiple risk factor intervention trial: Risk factor changes and mortality results. JAMA 1982; 248: 1465–1477.
- 8 Strandberg TE, Salomaa VV, Naukkarinen VA, Vanhanen HT, Sarna SJ, Miettinen TA: Long-term mortality after 5-year multifactorial primary prevention of cardiovascular disease in middle-aged men. JAMA 1991; 266: 1225–1229.
- 9 Materson BJ, Preston RA: Classic therapeutic trials in hypertension: Were patients vulnerable to unsuppressed peak morning blood pressure? Am J Hypertens 1991; 4(suppl): 449S–453S.
- 10 Davies MJ, Woolf N: Atherosclerosis: what is it and why does it occur? Br Heart J 1993; 69(suppl): S3–S11.
- 11 Doyle E: The Australian Therapeutic Trial in Mild Hypertension. Nephron 1987; 47(suppl): 115–119.
- 12 Cruickshank JM, Pennert K, Sorman E, Thorp JM, Zacharias FM, Zacharias FJ: Low mortality from all causes, including myocardial infarction, in well-controlled hypertensives treated with a beta-blocker plus other antihypertensives. J Hypertens 1987; 5: 489–498.
- 13 Badimon JJ, Fuster V, Cheseboro JH, Badimon L: Coronary atherosclerosis a multifactorial disease. Circulation 1993; 87(suppl II): II3–II16.
- 14 Lardinois CK, Neuman SL: The effects of antihypertensive agents on serum lipids and lipoproteins. Arch Intern Med 1988; 148: 1280–1288.
- 15 Vyssoulis GP, Karpanou EA, Pitsavos CE, Skoumas JN, Paleologos AA, Toutouzas PK: Differentiation of beta-blocker effects on serum lipids and apolipoproteins in hypertensive patients with normolipidemic or dyslipidemic profiles. Eur Heart J 1992; 13: 1506–1513.
- 16 Leren P: The hypertension—CHD dilemma. Acta Med Scand 1985; 217: 14–17.
- 17 Hjermann I: Primary prevention of coronary heart disease. Acta Med Scand 1985; 218: 1–4.
- 18 Moller LF, Jespersen J: Fasting serum insulin levels and coronary heart disease in a Danish cohort. J Cardiovasc Risk 1995; 2: 235–240.
- 19 Pederson TR. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389.
- 20 Chan P, Tomlinson B, Lee CB, Lee YS: Effectiveness and safety of low dose pravastatin and squalene, alone and in combination in elderly patients with hypercholesterolemia. J Clin Pharmacol 1996; 36: 422–427.
- 21 Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952–957.
- 22 Möller LF, Jespersen J: Fasting serum insulin levels and coronary heart disease in a Danish cohort: 17-year follow-up. J Cardiovasc Risk 1995; 2: 235–240.
- 23 Pyörälä K: Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: Results from two population studies in Finland. Diabetes Care 1979; 2: 131–134.
- 24 Chan P, Lee CB, Lin TS, Ko JT, Pan WH, Lee YS: The effectiveness and safety of low dose pravastatin in elderly hypertensive hyper-cholesterolemic subjects on antihypertensive therapy. Am J Hypertens 1995; 8: 1099–1104.
- 25 Chan P, Tomlinson B, Lee CB, Pan WH, Lee YS: Beneficial effects of pravastatin on fasting hyperinsulinemia in elderly hypertensive hypercholesterolemic subjects. Hypertension 1996; 28: 647–651.
- 26 Cholesterol Adult Treatment Panel: Report of the National Cholesterol Education Program expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Arch Intern Med 1988; 148: 36–69.
- 27 Lopes-Virella MF, Stone P, Ellis S, Colwell JA: Cholesterol determination in high density lipoproteins separated by three different methods. Clin Chem 1977; 23: 882–884.
- 28 Friedewald WT, Levy RI, Frederikson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502.
- 29 World Health Organization: Arterial Hypertension of WHO Expert Committee. Geneva: World Health Organization, Technical Report Series No. 628, 1978.
- 30
Dawber TR: The Framingham Study: The Epidemiology of Atherosclerosis Disease. Cambridge, MA: Harvard University Press, 1980.
10.4159/harvard.9780674492097 Google Scholar
- 31 Brown MS, Goldstein JL: How LDL receptors influence cholesterol and atherosclerosis. Sci Am 1984; 251: 58–66.
- 32 Plosker GL, McTavish D: Simvastatin: a reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolemia. Drugs 1995; 50: 334–363.
- 33 Morgan T, Anderson A, McDonald P, Hopper J, Macaskill G: Simvastatin in the treatment of hypercholesterolemia in patients with essential hypertension. J Hypertens 1990; 8(suppl 1): S25–S32.
- 34
Fujioka Y,
Ikegami H,
Fukuda M,
Kawaguchi Y,
Takegawak, Fujisawa T, et al: The effect on age for the relationship between hypertension and glucose intolerance.
Nippon Ronen Igakkai Zasshi
1993; 307: 622–625.
10.3143/geriatrics.30.622 Google Scholar
- 35 Paolisso G, Sgambato S, De Riu S, Gambardella A, Verza M, Varricchio M, D'Onofrio F: Simvastatin reduces plasma lipid levels and improves insulin action in elderly, non-insulin dependent diabetes. Eur J Clin Pharmacol 1991; 40: 27–31.